Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Clobetasone→

Clobetasone Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
54063-32-0
Molecular formula
C22H27FO4
Molecular weight
374.5 g/mol
Drug class
Moderately potent topical corticosteroid (clobetasone butyrate)
Mechanism of action
Activates intracellular glucocorticoid receptors and alters transcription of inflammatory mediators, reducing inflammatory, pruritic and immunological responses in the skin.
Indications / reported uses
  • Short-term treatment of steroid-responsive inflammatory dermatoses, including milder eczema and dermatitis; strength, age limits and duration depend on the specific formulation

Sources: Australian Commission on Safety and Quality in Health Care — Kloxema (clobetasone butyrate) · UK SmPC — Eumovate ointment · FDA product information

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Clobetasone Environmental Risk Assessment (ERA) (the Clobetasone ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.